Loading clinical trials...

Oral Corticosteroids for Post-infectious Cough in Adults | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Oral Corticosteroids for Post-infectious Cough in Adults

Oral Corticosteroids for Post-infectious Cough in Adults: A Double-blind Randomised Placebo-controlled Trial in Swiss Family Practices (OSPIC Trial)

NCT04232449•University Hospital, Basel, Switzerland

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess whether a 5-day treatment with orally administered prednisone provides patient-relevant benefits by improving the cough-related QoL of patients with post-infectious cough triggered by an Upper Respiratory Tract Infection (URTI) and seeking care in adult primary care practices. The study aims to describe an efficacy and safety profile for a 5-day prednisone treatment compared to a 5-day course of placebo.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients seeing a GP for a dry or productive post-infectious cough (3 to 8 weeks) after Upper Respiratory Tract Infection (URTI)
•Patients able and willing to give informed consent by themselves and to fill in the LCQ on day 0 with the GP and to answer phone calls from the research staff/study nurse at day 7, 14, and 28, and at 3 months for outcome assessment

Exclusion Criteria

•Patients with known or suspected diagnoses associated with cough, such as: pneumonia or suggestive symptoms and signs (abnormal vital signs, i.e. heart rate \>100/min, respiratory rate \>25/min, fever), allergic rhinitis, sinusitis, bronchial asthma, chronic pulmonary disease (COPD), or gastroesophageal reflux disease,
•Patients with other chronic disease such as bronchiectasis, cystic fibrosis, cancer, tuberculosis, heart failure.
•Use of inhaled or oral corticosteroids within the last four weeks
•Immunodeficiency/immunocompromised state (e.g. cancer chemotherapy, HIV infection, administration of immune-suppressive agents)
•Pregnancy/ breastfeeding
•Regular treatment known to be associated with cough (e.g. angiotensin converting enzyme inhibitors)
•Patients with pharmacotherapy for glaucoma or osteoporosis
•Experienced fractures due to osteoporosis
•Patients with uncontrolled diabetes (as deemed by GPs who appraise whether the potential side effects of short-time corticosteroids on glucose levels exceed the hypothesised benefit on cough)

Locations (2)

Centre for Primary Health Care (uniham-bb); University of Basel; Kantonsspital Baselland

Liestal, Switzerland

Institute of Primary and Community Care, University of Lucerne

Lucerne, Switzerland

Key Dates

Start Date

November 6, 2020

Primary Completion Date

April 30, 2024

Completion Date

April 30, 2024

Last Updated

July 3, 2024

Enrollment

ACTUAL participants

Conditions

Post-infectious Cough

Interventions

PREDNISON Galepharm Tabl. 20 mg

DRUG

placebo tablets

DRUG

Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial

NCT07103980

Post-Infectious Cough

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions